Melanoma Staging and Treatment: Immunotherapy and Targeted Therapy
AJCC 8th Edition Staging and Prognostic Factors
The AJCC 8th edition staging system for cutaneous melanoma uses Breslow thickness, ulceration, and mitotic rate as primary tumor prognostic factors. T1a lesions (less than 0.8 mm, non-ulcerated) carry a 10-year melanoma-specific survival of 98%, while T4b lesions (greater than 4.0 mm, ulcerated) have a 10-year survival of 75%. Sentinel lymph node biopsy is recommended for lesions with Breslow thickness above 0.8 mm or T1b (less than 0.8 mm with ulceration), based on MSLT-I data showing a 20% positivity rate in this population.
Immune Checkpoint Inhibitors in Advanced Melanoma
The CheckMate 067 trial established nivolumab plus ipilimumab as the benchmark for first-line metastatic melanoma treatment, achieving a 6.5-year overall survival rate of 49% for the combination versus 42% for nivolumab monotherapy and 23% for ipilimumab monotherapy. However, grade 3-4 adverse events occurred in 59% of combination-treated patients. The RELATIVITY-047 trial demonstrated relatlimab plus nivolumab (Opdualag) as an alternative with a more favorable toxicity profile: progression-free survival of 10.1 months versus 4.6 months for nivolumab monotherapy (HR 0.75, p=0.006) with grade 3-4 events in 21%.
BRAF-Targeted Therapy
Approximately 40-50% of cutaneous melanomas harbor BRAF V600E/K mutations. The COLUMBUS trial demonstrated encorafenib plus binimetinib achieves a median PFS of 14.9 months and OS of 33.6 months. Current NCCN guidelines recommend first-line immunotherapy over targeted therapy for most BRAF-mutant patients, reserving BRAF/MEK inhibition for patients requiring rapid tumor response (brain metastases, high tumor burden with symptomatic disease) or those who progress on immunotherapy. The DREAMseq trial confirmed this sequencing, showing 2-year OS of 72% for immunotherapy-first versus 52% for targeted therapy-first (p=0.0095).
Sponsored
Adjuvant Therapy: Stage III and High-Risk Stage II
Pembrolizumab (KEYNOTE-054) and nivolumab (CheckMate 238) are both approved for adjuvant therapy in resected stage III melanoma. KEYNOTE-054 showed a 4-year recurrence-free survival of 54.4% versus 42.1% for placebo. The KEYNOTE-716 trial extended adjuvant pembrolizumab to high-risk stage IIB/IIC disease, demonstrating a 35% reduction in distant metastasis-free survival events (HR 0.64, p=0.0029). Adjuvant dabrafenib plus trametinib is an alternative for BRAF-mutant stage III patients per the COMBI-AD trial (5-year RFS 52% versus 36%).
Neoadjuvant Immunotherapy: The Emerging Frontier
The SWOG S1801 trial demonstrated that neoadjuvant pembrolizumab (3 cycles before surgery, 15 cycles after) improved 2-year event-free survival to 72% versus 49% for adjuvant-only pembrolizumab in resectable stage IIIB-IV melanoma (HR 0.59, p=0.004). Pathologic complete response rates of 25-30% with dual checkpoint blockade are being explored in the NADINA trial (neoadjuvant nivolumab plus ipilimumab), with early results showing pCR in 59% of patients. These findings are reshaping the treatment paradigm toward a neoadjuvant-first approach for resectable high-risk disease.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.